retention and abstinence, all patients · patients with opioid dependence
naltrexone showed no clear difference in retention and abstinence, all patients compared with placebo or no pharmacological treatments; GRADE not reported.
1 finding from 1 review
Abstinence · patients with opioid dependence
naltrexone showed no clear difference in abstinence at compared with placebo or no pharmacological treatments; GRADE not reported.
1 finding from 1 review
Side effects · patients with opioid dependence
naltrexone showed no clear difference in side effects compared with placebo or no pharmacological treatments; GRADE not reported.
1 finding from 1 review
Rescue free laxation within 4 hours · patients with the management of opioid‐induced constipation in palliative care patients
Methylnaltrexone probably leads to higher rescue free laxation within 4 hours compared with placebo (moderate certainty).
1 finding from 1 review
Rescue free laxation within 24 hours · patients with the management of opioid‐induced constipation in palliative care patients
Methylnaltrexone probably leads to higher rescue free laxation within 24 hours compared with placebo (moderate certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in induction of clinical remission CDAI < 150 compared with placebo (low certainty).
1 finding from 1 review
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
Low dose naltrexone may leads to higher induction of 70‐point clinical response CDAI compared with placebo (low certainty).
1 finding from 1 review
Induction of 5‐point endoscopic response CDEIS · Patients with active Crohn's disease
Low dose naltrexone may leads to higher induction of 5‐point endoscopic response CDEIS compared with placebo (low certainty).
1 finding from 1 review
Sleep disturbance (adverse event) · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in sleep disturbance (adverse event) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in withdrawals due to adverse outcomes compared with placebo (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to higher laxation response: risk of spontaneous rescue‐free bowel… compared with placebo (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone probably leads to higher laxation response: risk of spontaneous rescue‐free bowel… compared with placebo (moderate certainty).
1 finding from 1 review
Laxation response: patient assessment of change in bowel status at the end of trial · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to higher laxation response: patient assessment of change in bowel statusgat… compared with placebo (low certainty).
1 finding from 1 review
Symptoms of opioid withdrawal in the medium term · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone showed no clear difference in symptoms of opioid withdrawalhin the medium term compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsi · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to lower serious adverse eventsi compared with placebo (low certainty).
1 finding from 1 review
Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in total mortality compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in cardiovascular morbidity compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion probably leads to higher all adverse events compared with placebo (moderate certainty).
1 finding from 1 review